Literature DB >> 34081328

Evaluation of the performance of SARS--CoV--2 antibody assays for a longitudinal population-based study of COVID--19 spread in St. Petersburg, Russia.

Anton Barchuk1,2, Daniil Shirokov3,4, Mariia Sergeeva5, Rustam Tursun Zade1, Olga Dudkina1, Varvara Tychkova6, Lubov Barabanova3, Dmitriy Skougarevskiy7, Daria Danilenko6.   

Abstract

Geographical variation in severe acute respiratory syndrome coronavirus 2 (SARS--CoV--2) spread requires seroprevalence studies based on local tests, but robust validation is needed. We summarize an evaluation of antibody tests used in a serological study of SARS--CoV--2 in Saint Petersburg, Russia. We validated three different antibody assays: chemiluminescent microparticle immunoassay (CMIA) Abbott Architect SARS--CoV--2 immunoglobulin G (IgG), enzyme- linked immunosorbent assay (ELISA) CoronaPass total antibodies test, and ELISA SARS--CoV--2--IgG--EIA--BEST. Clinical sensitivity was estimated with the SARS--CoV--2 polymerase chain reaction (PCR) test as the gold standard using manufacturer recommended cutoff. Specificity was estimated using pre-pandemic sera samples. The median time between positive PCR test results and antibody tests was 21 weeks. Measures of concordance were calculated against the microneutralization test (MNA).Sensitivity was equal to 91.1% (95% confidence intervbal [CI]: 78.8-97.5), 90% (95% CI: 76.4-96.4), and 63.1% (95% CI [50.2-74.7]) for ELISA Coronapass, ELISA Vector-Best, and CMIA Abbott, respectively. Specificity was equal to 100% for all the tests. Comparison of receiver operating characteristics has shown lower AUC for CMIA Abbott. The cut-off SC/O ratio of 0.28 for CMIA Abbott resulted in a sensitivity of 80% at the same level of specificity. Less than 33% of the participants with positive antibody test results had neutralizing antibodies in titers 1:80 and above. Antibody assays results and MNA correlated moderately. This study encourages the use of local antibody tests and sets the reference for seroprevalence correction. Available tests' sensitivity allows detecting antibodies within the majority of PCR- positive individuals. The Abbott assay sensitivity can be improved by incorporating a new cut-off. Manufacturers' test characteristics may introduce bias into the study results.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  COVID­19; SARS­CoV­2; SARS­CoV­2 infection antibody testing; seroepidemiologic study

Mesh:

Substances:

Year:  2021        PMID: 34081328      PMCID: PMC8242745          DOI: 10.1002/jmv.27126

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   20.693


  25 in total

1.  Evaluation of the performance of SARS--CoV--2 antibody assays for a longitudinal population-based study of COVID--19 spread in St. Petersburg, Russia.

Authors:  Anton Barchuk; Daniil Shirokov; Mariia Sergeeva; Rustam Tursun Zade; Olga Dudkina; Varvara Tychkova; Lubov Barabanova; Dmitriy Skougarevskiy; Daria Danilenko
Journal:  J Med Virol       Date:  2021-06-12       Impact factor: 20.693

2.  The paramount importance of serological surveys of SARS-CoV-2 infection and immunity.

Authors:  Jaap Goudsmit
Journal:  Eur J Epidemiol       Date:  2020-04-21       Impact factor: 8.082

Review 3.  SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis.

Authors:  Ali Rostami; Mahdi Sepidarkish; Mariska M G Leeflang; Seyed Mohammad Riahi; Malihe Nourollahpour Shiadeh; Sahar Esfandyari; Ali H Mokdad; Peter J Hotez; Robin B Gasser
Journal:  Clin Microbiol Infect       Date:  2020-10-24       Impact factor: 8.067

4.  Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by virus neutralization and commercial assays.

Authors:  Antonin Bal; Mary-Anne Trabaud; Jean-Baptiste Fassier; Muriel Rabilloud; Kahina Saker; Carole Langlois-Jacques; Nicolas Guibert; Adèle Paul; Dulce Alfaiate; Amélie Massardier-Pilonchery; Virginie Pitiot; Florence Morfin-Sherpa; Bruno Lina; Bruno Pozzetto; Sophie Trouillet-Assant
Journal:  Clin Microbiol Infect       Date:  2021-01-13       Impact factor: 8.067

5.  An evaluation of 4 commercial assays for the detection of SARS-CoV-2 antibodies in a predominantly mildly symptomatic low prevalence Australian population.

Authors:  Michael C Wehrhahn; Suzanne J Brown; James P Newcombe; Smathi Chong; Jenny Evans; Melanie Figtree; Laurence Hainke; Linda Hueston; Sadid Khan; Elizabeth Marland; Matthew V N O'Sullivan; Helen Powell; Jhumur Roy; Lynette Waring; Megan Yu; Jennifer Robson
Journal:  J Clin Virol       Date:  2021-03-17       Impact factor: 3.168

6.  Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays.

Authors:  Lisa Weidner; Simon Gänsdorfer; Stephan Unterweger; Lukas Weseslindtner; Camilla Drexler; Maria Farcet; Volker Witt; Elisabeth Schistal; Peter Schlenke; Thomas R Kreil; Christof Jungbauer
Journal:  J Clin Virol       Date:  2020-07-06       Impact factor: 3.168

7.  Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection.

Authors:  K L Chew; S S Tan; S Saw; A Pajarillaga; S Zaine; C Khoo; W Wang; P Tambyah; R Jureen; S K Sethi
Journal:  Clin Microbiol Infect       Date:  2020-06-09       Impact factor: 8.067

8.  Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients.

Authors:  Frauke Muecksch; Helen Wise; Becky Batchelor; Maria Squires; Elizabeth Semple; Claire Richardson; Jacqueline McGuire; Sarah Clearly; Elizabeth Furrie; Neil Greig; Gordon Hay; Kate Templeton; Julio C C Lorenzi; Theodora Hatziioannou; Sara Jenks; Paul D Bieniasz
Journal:  J Infect Dis       Date:  2021-02-13       Impact factor: 5.226

9.  Humoral Immune Response to SARS-CoV-2 in Iceland.

Authors:  Daniel F Gudbjartsson; Gudmundur L Norddahl; Pall Melsted; Kristbjorg Gunnarsdottir; Hilma Holm; Elias Eythorsson; Asgeir O Arnthorsson; Dadi Helgason; Kristbjorg Bjarnadottir; Ragnar F Ingvarsson; Brynja Thorsteinsdottir; Steinunn Kristjansdottir; Kolbrun Birgisdottir; Anna M Kristinsdottir; Martin I Sigurdsson; Gudny A Arnadottir; Erna V Ivarsdottir; Margret Andresdottir; Frosti Jonsson; Arna B Agustsdottir; Jonas Berglund; Berglind Eiriksdottir; Run Fridriksdottir; Elisabet E Gardarsdottir; Magnus Gottfredsson; Olafia S Gretarsdottir; Steinunn Gudmundsdottir; Kjartan R Gudmundsson; Thora R Gunnarsdottir; Arnaldur Gylfason; Agnar Helgason; Brynjar O Jensson; Aslaug Jonasdottir; Hakon Jonsson; Thordur Kristjansson; Karl G Kristinsson; Droplaug N Magnusdottir; Olafur T Magnusson; Lovisa B Olafsdottir; Solvi Rognvaldsson; Louise le Roux; Gudrun Sigmundsdottir; Asgeir Sigurdsson; Gardar Sveinbjornsson; Kristin E Sveinsdottir; Maney Sveinsdottir; Emil A Thorarensen; Bjarni Thorbjornsson; Marianna Thordardottir; Jona Saemundsdottir; S Hjortur Kristjansson; Kamilla S Josefsdottir; Gisli Masson; Gudmundur Georgsson; Mar Kristjansson; Alma Moller; Runolfur Palsson; Thorolfur Gudnason; Unnur Thorsteinsdottir; Ingileif Jonsdottir; Patrick Sulem; Kari Stefansson
Journal:  N Engl J Med       Date:  2020-09-01       Impact factor: 91.245

10.  Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.

Authors:  Sheila F Lumley; Denise O'Donnell; Nicole E Stoesser; Philippa C Matthews; Alison Howarth; Stephanie B Hatch; Brian D Marsden; Stuart Cox; Tim James; Fiona Warren; Liam J Peck; Thomas G Ritter; Zoe de Toledo; Laura Warren; David Axten; Richard J Cornall; E Yvonne Jones; David I Stuart; Gavin Screaton; Daniel Ebner; Sarah Hoosdally; Meera Chand; Derrick W Crook; Anne-Marie O'Donnell; Christopher P Conlon; Koen B Pouwels; A Sarah Walker; Tim E A Peto; Susan Hopkins; Timothy M Walker; Katie Jeffery; David W Eyre
Journal:  N Engl J Med       Date:  2020-12-23       Impact factor: 91.245

View more
  9 in total

1.  Hybrid Proteins with Short Conformational Epitopes of the Receptor-Binding Domain of SARS-CoV-2 Spike Protein Promote Production of Virus-Neutralizing Antibodies When Used for Immunization.

Authors:  Anna S Karyagina; Alexander V Gromov; Tatyana M Grunina; Alexander M Lyaschuk; Maria S Poponova; Denis A Kleymenov; Natalia V Strukova; Maria S Generalova; Anna V Ryazanova; Zoya M Galushkina; Olga Yu Dobrynina; Tatyana N Bolshakova; Maria V Sergeeva; Ekaterina A Romanovskaya-Romanko; Igor V Krasilnikov; Marina E Subbotina; Vladimir G Lunin
Journal:  Biochemistry (Mosc)       Date:  2022-04       Impact factor: 2.487

2.  Assessing the burden of COVID-19 in developing countries: systematic review, meta-analysis and public policy implications.

Authors:  Andrew T Levin; Nana Owusu-Boaitey; Sierra Pugh; Bailey K Fosdick; Anthony B Zwi; Anup Malani; Satej Soman; Lonni Besançon; Ilya Kashnitsky; Sachin Ganesh; Aloysius McLaughlin; Gayeong Song; Rine Uhm; Daniel Herrera-Esposito; Gustavo de Los Campos; Ana Carolina Pecanha Peçanha Antonio; Enyew Birru Tadese; Gideon Meyerowitz-Katz
Journal:  BMJ Glob Health       Date:  2022-05

3.  Evaluation of the performance of SARS--CoV--2 antibody assays for a longitudinal population-based study of COVID--19 spread in St. Petersburg, Russia.

Authors:  Anton Barchuk; Daniil Shirokov; Mariia Sergeeva; Rustam Tursun Zade; Olga Dudkina; Varvara Tychkova; Lubov Barabanova; Dmitriy Skougarevskiy; Daria Danilenko
Journal:  J Med Virol       Date:  2021-06-12       Impact factor: 20.693

4.  Seroprevalence of SARS-Cov-2 Antibodies in Adults, Arkhangelsk, Russia.

Authors:  Ekaterina Krieger; Alexander Kudryavtsev; Ekaterina Sharashova; Vitaly Postoev; Natalia Belova; Leonid Shagrov; Julia Zvedina; Oxana Drapkina; Anna Kontsevaya; Svetlana Shalnova; Tormod Brenn; Vladimir M Shkolnikov; Rosalind M Eggo; David A Leon
Journal:  Emerg Infect Dis       Date:  2022-02       Impact factor: 6.883

5.  Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose.

Authors:  Oktavija Đaković Rode; Kristian Bodulić; Sanja Zember; Nataša Cetinić Balent; Anđa Novokmet; Marija Čulo; Željka Rašić; Radojka Mikulić; Alemka Markotić
Journal:  Vaccines (Basel)       Date:  2022-01-20

6.  Dynamic of humoral response to SARS-CoV-2 anti-Nucleocapsid and Spike proteins after CoronaVac vaccination.

Authors:  Lucas Bochnia-Bueno; Sergio Monteiro De Almeida; Sonia Mara Raboni; Douglas Adamoski; Ludmilla Louise Moreira Amadeu; Suzana Carstensen; Meri Bordignon Nogueira
Journal:  Diagn Microbiol Infect Dis       Date:  2021-11-19       Impact factor: 2.803

7.  Seropositivity of SARS-CoV-2 in the Population of Kazakhstan: A Nationwide Laboratory-Based Surveillance.

Authors:  Yuliya Semenova; Zhanna Kalmatayeva; Ainash Oshibayeva; Saltanat Mamyrbekova; Aynura Kudirbekova; Ardak Nurbakyt; Ardak Baizhaxynova; Paolo Colet; Natalya Glushkova; Alexandr Ivankov; Antonio Sarria-Santamera
Journal:  Int J Environ Res Public Health       Date:  2022-02-17       Impact factor: 3.390

8.  COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.

Authors:  Anton Barchuk; Dmitriy Skougarevskiy; Alexei Kouprianov; Daniil Shirokov; Olga Dudkina; Rustam Tursun-Zade; Mariia Sergeeva; Varvara Tychkova; Andrey Komissarov; Alena Zheltukhina; Dmitry Lioznov; Artur Isaev; Ekaterina Pomerantseva; Svetlana Zhikrivetskaya; Yana Sofronova; Konstantin Blagodatskikh; Kirill Titaev; Lubov Barabanova; Daria Danilenko
Journal:  PLoS One       Date:  2022-06-15       Impact factor: 3.752

Review 9.  Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Authors:  Zhi Xiong Chong; Winnie Pui Pui Liew; Hui Kian Ong; Chean Yeah Yong; Chong Seng Shit; Wan Yong Ho; Stephanie Y L Ng; Swee Keong Yeap
Journal:  Pathol Res Pract       Date:  2021-07-24       Impact factor: 3.250

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.